KCNH2 and metastatic colorectal cancer: In particular in breast tumours where hERG1 channel expression contributes to identify patients with better outcome [17] and the same happens in patient bearing metastatic colorectal cancer and treated with bevacizumab [31] differently from what is observed in non-metastatic patients [44].